BioGaia sees sales, profits rise

15 Apr 2015

Swedish probiotics company BioGaia has reported annual sales up 22% to SEK384.6m on a like for like basis and profit after tax (PAT) up from SEK64.2m to SEK73.6m. Including license revenues from Nestlé, sales increased by 53% to SEK481.8m and PAT to SEK148.0m. “With sales growth of 22 per cent and an operating margin of […]

BioGaia sees sales, profits rise

http://www.dreamstime.com/royalty-free-stock-photos-rising-graph-blackboard-image18391908Swedish probiotics company BioGaia has reported annual sales up 22% to SEK384.6m on a like for like basis and profit after tax (PAT) up from SEK64.2m to SEK73.6m. Including license revenues from Nestlé, sales increased by 53% to SEK481.8m and PAT to SEK148.0m.

“With sales growth of 22 per cent and an operating margin of 26 per cent, 2014 can only be summed up as a successful year,” said Peter Rothschild, Founder And President, Biogaia. “Although one of our most important markets, Ukraine, declined significantly during the year, this negative trend was offset by very strong development in Brazil, where we launched during the autumn. It is gratifying to see that nearly all of our markets are growing at a solid pace and that the BioGaia brand is becoming more and more established, particularly among paediatricians, as the safest and most effective probiotic on the market.”

“During the year we also succeeded in signing agreements to introduce our products in a few major markets such as the UK and India, where we are now working intensively to ensure successful launches. In light of the potential in these markets and Brazil, where we are off to an excellent start, I am optimistic about 2015 and expect BioGaia to maintain a high rate of growth. At the same time, we are continuing to focus on further clinical studies and product development and are investing in TwoPac and IBT. I therefore anticipate strong growth in the company in both the short and long term.